ImmunityBio (IBRX) Liabilities and Shareholders Equity (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $646.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 112.88% year-over-year to $646.6 million in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 38.38% increase from a year earlier, with the FY2025 full-year figure at $501.9 million, up 31.07% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $646.6 million, up from $501.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for IBRX reached as high as $646.6 million in Q1 2026 and fell as low as $291.2 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $409.4 million across 5 years, with a median of $389.6 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity retreated 24.19% in 2025 and soared 112.88% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $362.4 million in 2022, then surged by 39.21% to $504.5 million in 2023, then declined by 24.09% to $382.9 million in 2024, then surged by 31.07% to $501.9 million in 2025, then rose by 28.84% to $646.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $646.6 million in Q1 2026, $501.9 million in Q4 2025, and $519.0 million in Q3 2025.